What Conmed Stock’s History Says About Catching This Falling Knife
The medical device maker is sharpening its focus, but its track record for rewarding dip-buyers is less than sharp.
Conmed (CNMD) is making some decisive moves. The company is selling off its gastroenterology product lines to double down on what it sees as its future: higher-growth platforms like AirSeal, Buffalo Filter, and BioBrace. Management calls it an intentional and strategic decision to “concentrate resources and investment on our higher growth, higher-margin offerings.” Yet, the stock has fallen about 14% in just the past few weeks, and over the trailing twelve months it has returned -39.6%.
That kind of pullback always gets investors thinking. Is this a chance to buy into a newly focused company at a better price, or is it a warning sign? Let’s look at the evidence, starting with what history says about buying a dip like this one in CNMD.
What History Says About Buying Conmed Dips
- What GE Vernova Stock’s Shadow Backlog Was Saying Before The Surge
- The Number That Puts Oracle Stock To The Test
- The Secret Chip Company That Could Power Amazon Stock Higher
- Is GE Stock’s Large Backlog Enough To Out-Fly a Slowdown?
- Does CAT Stock’s Surge Offer Your Portfolio Real Power Or Just More Market Risk?
- What Could Go Wrong For Adobe Stock?
A sharp dip isn’t automatically a bargain, and for Conmed, the historical record urges caution. The stock has seen a steep drop of 20% or more within a month on 13 separate occasions since 2010. Of those 13 instances, only 5 were followed by a positive return over the next year. The median outcome for investors who bought in was a one-year loss of negative 8%. Even when the stock did eventually recover, buyers first had to stomach a median worst further drawdown of 25%. The past doesn’t predict the future, but this track record suggests that buying a steep drop in CNMD has historically been a tough road.
CNMD had 13 events since 1/1/2010, where the dip threshold of -20% within 30 days was triggered
- 26% median peak return within 1 year of dip event
- 214 days is the median time to peak return after a dip event
- -25% median max drawdown within 1 year of dip event
| Period | Past Median Return |
|---|---|
| 1M | 0.7% |
| 3M | -2.6% |
| 6M | 1.2% |
| 12M | -7.7% |
| 30 Day Dip | CNMD Subsequent Performance | |||||||
|---|---|---|---|---|---|---|---|---|
| Date | CNMD | SPY | 1Y | Peak Return |
Max Drop |
# Days to Peak |
||
| Median | -8% | 26% | -25% | 214 | ||||
| 4022026 | -22% | -4% | -8% | 14% | -8% | 12 | ||
| 10102025 | -20% | 1% | -25% | 14% | -25% | 12 | ||
| 4212025 | -24% | -11% | -19% | 27% | -29% | 21 | ||
| 3202025 | -20% | -6% | -37% | 3% | -39% | 4 | ||
| 4252024 | -28% | -2% | -16% | 26% | -22% | 214 | ||
| 2012024 | -23% | 4% | -12% | 5% | -26% | 11 | ||
| 8182023 | -20% | -0% | -35% | 10% | -41% | 118 | ||
| 9262022 | -22% | -14% | 23% | 72% | -9% | 262 | ||
| 5092022 | -25% | -12% | 16% | 19% | -33% | 353 | ||
| 3092020 | -24% | -17% | 51% | 55% | -52% | 352 | ||
| 10222015 | -21% | 5% | -0% | 26% | -10% | 267 | ||
| 8102011 | -22% | -13% | 26% | 41% | -4% | 237 | ||
| 5252010 | -20% | -10% | 42% | 51% | -12% | 350 | ||
[2] Analysis for period from 1/1/2010 to 6/17/2026
But Buying The Dip Demands A Healthy Business
Of course, you’re buying a business, not just a stock chart. A dip in a struggling company is a trap, while a dip in a solid one can be an opportunity. On that front, Conmed’s underlying business appears sound. The company clears every basic quality check on a simple scorecard of growth, cash generation, and balance-sheet strength. Trailing twelve-month revenue grew 4.1%, and its operating cash flow margin is a healthy 10.4%. These aren’t signs of a business in distress; they point to a stable operation navigating a strategic shift.
| Quality Metrics | Value | Quality Check |
|---|---|---|
| Revenue Growth (LTM) | 4.1% | Pass |
| Revenue Growth (3-Yr Avg) | 7.8% | Pass |
| Operating Cash Flow Margin (LTM) | 10.4% | Pass |
| Leverage (see below) | – | Pass |
| => Interest Coverage Ratio | 3.7 | |
| => Cash To Interest Expense Ratio | 1.2 |
Is This Dip Different From The Last Ones?
So, is this dip different? The bull case is that you’re getting a more focused, higher-quality medical device company at a valuation that now looks low. After the drop, CNMD trades at a price-to-earnings ratio of about 18, compared to roughly 24 for its peers. Management is confident enough to have raised its organic growth expectation for 2026 to a range of 5.0% to 6.5%.
The catch is the reason for the market’s recent anxiety. The company plans to refinance its debt, which it expects will create a new headwind, “impacting adjusted EPS for the full year by at least $0.10.” That’s a tangible hit to the bottom line. Furthermore, hitting that raised growth guidance requires a significant acceleration from the 2.1% organic growth reported in the first quarter, a jump that made analysts on the earnings call question the “larger-than-normal step-up” required.
Ultimately, the decision comes down to this: Do you believe the company’s strategic pivot can generate enough growth to overcome both the poor historical odds for dip-buyers and a new, concrete drag on earnings? The key thing to watch in the next earnings report is whether that growth acceleration actually materializes. That will be the first real sign of whether this dip is an opportunity or just another chapter in a familiar story.
Wondering which other quality stocks have just sold off, and whether their past dips have tended to recover? You can screen the market’s recent pullbacks on our Buy The Dip rankings.
Beyond Timing A Single Dip
Buying the dip on one stock looks easy on a chart, but living through it is hard. A “bargain” that keeps falling, tests your nerve, and the temptation to sell at the bottom is exactly what derails most dip buyers. Catching the rebound takes a plan that makes staying invested a discipline rather than a test of willpower. That is the idea behind the Trefis High Quality (HQ) Portfolio, which holds 30 quality stocks, sized and rebalanced with discipline, and has a track record of outpacing a benchmark that combines all major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Pairing a single-name dip with a diversified core is how you keep the upside while smoothing the swings that shake investors out at the worst moment.